Alendronate or Alfacalcidol in Glucocorticoid-Induced Osteoporosis

Abstract

During this 18-month trial in patients with rheumatic diseases, alendronate was more effective in the prevention of glucocorticoid-induced bone loss than was alfacalcidol. (ClinicalTrials.gov number, NCT00138983 [ClinicalTrials.gov].).